NO20060730L - Humane antistoffmolekyler mot IL-13 - Google Patents

Humane antistoffmolekyler mot IL-13

Info

Publication number
NO20060730L
NO20060730L NO20060730A NO20060730A NO20060730L NO 20060730 L NO20060730 L NO 20060730L NO 20060730 A NO20060730 A NO 20060730A NO 20060730 A NO20060730 A NO 20060730A NO 20060730 L NO20060730 L NO 20060730L
Authority
NO
Norway
Prior art keywords
antibody molecules
human antibody
molecules against
hodgkin
fibrosis
Prior art date
Application number
NO20060730A
Other languages
English (en)
Other versions
NO338853B1 (no
Inventor
Phillip David Monk
Celia Patricia Shorrock
Original Assignee
Cambridge Antibody Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0407315.1A external-priority patent/GB0407315D0/en
Application filed by Cambridge Antibody Tech filed Critical Cambridge Antibody Tech
Publication of NO20060730L publication Critical patent/NO20060730L/no
Publication of NO338853B1 publication Critical patent/NO338853B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Spesifikke bindingsmedlemmer, spesielt humane anti IL-13 antistoffmolekyler og spesielt de som nøytraliserer IL-I3 aktivitet. Fremgangsmåter for å anvende anti IL-I3 antistoffmolekyler i diagnose eller behandling av IL-I3 relaterte forstyrrelser, inkludert astma, atopisk dermatitt, allergisk rinitt, fibrose, inflammatorisk bowel sykdom og Hodgkin's lymfoma.
NO20060730A 2003-07-15 2006-02-15 Isolert spesifikt bindingsmedlem for humant IL-13, isolert antistoff VH og VL domene, sammensetning inneholdende disse og fremgangsmåter for å fremstille disse og anvendelse, samt isolert nukleinsyre og vertscelle. NO338853B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US55821604P 2004-03-31 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US57379104P 2004-05-24 2004-05-24
PCT/GB2004/003059 WO2005007699A2 (en) 2003-07-15 2004-07-15 Human antibody molecules for il-13

Publications (2)

Publication Number Publication Date
NO20060730L true NO20060730L (no) 2006-04-10
NO338853B1 NO338853B1 (no) 2016-10-24

Family

ID=44535047

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20060730A NO338853B1 (no) 2003-07-15 2006-02-15 Isolert spesifikt bindingsmedlem for humant IL-13, isolert antistoff VH og VL domene, sammensetning inneholdende disse og fremgangsmåter for å fremstille disse og anvendelse, samt isolert nukleinsyre og vertscelle.
NO20160707A NO342727B1 (no) 2003-07-15 2016-04-27 Isolert spesifikt antistoffmolekyl mot humant IL-13, sammensetning inneholdende disse, fremgangsmåter for fremstilling og anvendelse, samt isolert nukleinsyre og 30 vertscelle.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20160707A NO342727B1 (no) 2003-07-15 2016-04-27 Isolert spesifikt antistoffmolekyl mot humant IL-13, sammensetning inneholdende disse, fremgangsmåter for fremstilling og anvendelse, samt isolert nukleinsyre og 30 vertscelle.

Country Status (8)

Country Link
JP (3) JP5519567B2 (no)
KR (1) KR101073590B1 (no)
AU (1) AU2011200308B2 (no)
CY (1) CY1111467T1 (no)
HK (3) HK1097853A1 (no)
MX (1) MXPA06000258A (no)
NO (2) NO338853B1 (no)
RU (1) RU2009148270A (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201811177SA (en) * 2014-06-18 2019-01-30 Medimmune Llc Cell culture methods and media comprising n-acetylcysteine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142860A1 (en) * 1992-08-21 1994-03-03 Gregorio Aversa Human interleukin-13
EP1578912A4 (en) * 2001-10-26 2007-12-26 Centocor Inc IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
EP1461428B1 (en) * 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Method for producing hybrid antibodies
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
AU2011200308B2 (en) 2011-07-28
NO20160707A1 (no) 2016-04-27
JP5922686B2 (ja) 2016-05-24
JP5519567B2 (ja) 2014-06-11
KR20060054312A (ko) 2006-05-22
RU2009148270A (ru) 2011-06-27
HK1155185A1 (zh) 2012-05-11
CY1111467T1 (el) 2015-08-05
KR101073590B1 (ko) 2011-10-14
AU2011200308A1 (en) 2011-02-17
HK1097853A1 (en) 2007-07-06
JP2014101372A (ja) 2014-06-05
NO338853B1 (no) 2016-10-24
JP2016047843A (ja) 2016-04-07
MXPA06000258A (es) 2006-07-03
HK1216427A1 (zh) 2016-11-11
JP2011147454A (ja) 2011-08-04
NO342727B1 (no) 2018-07-30

Similar Documents

Publication Publication Date Title
NO20082309L (no) Organiske molekyler
WO2005007699A3 (en) Human antibody molecules for il-13
GB0603683D0 (en) Organic compounds
CY1120874T1 (el) Συνθεση αντισωματος ιντερλευκινης-13
WO2005123126A3 (en) Antibodies against human interleukin-13 and uses therefor
WO2004090539A3 (en) Methods of determining efficacy of treatments of inflammatory diseases of the bowel
EP2286837A3 (en) Treatment of obesity and obesity related diseases
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2007146229A3 (en) Markers associated with arteriovascular events and methods of use thereof
DE602004030341D1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
Frisardi Impact of metabolic syndrome on cognitive decline in older age: protective or harmful, where is the pitfall?
EP2347767A3 (en) Immune regulation based on the targeting of early activation molecules
WO2007055743A3 (en) Treatment of obesity and related disorders
WO2006079068A3 (en) Compositions and methods for studying and treating inflammatory diseases and disorders
NO20060730L (no) Humane antistoffmolekyler mot IL-13
WO2003099105A3 (en) Diagnosis and treatment of human dormancy syndrome
WO2006048781A3 (en) IgE-RETARGETING, FUNCTION-ALTERING MOLECULES (ERFAM) FOR TREATMENT OF ALLERGIC DISEASES
TNSN08175A1 (en) Human antibodies against il-13 and therapeutic uses
WO2004094641A3 (en) A novel method of modulating bone-realted activity
De Luca et al. Should individuals with chronic aphasia be treated with dedicated PC-based training? Considerations about a case study
WO2006113723A3 (en) Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
WO2007076422A3 (en) Antibodies against interleukin-22 binding protein and its uses
RU2003111602A (ru) Способ диагностики степени выраженности нарушений высших мозговых функций